Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

Type
Public
HQ
Philadelphia, US
Founded
2008
Size (employees)
298 (est)+73%
Adaptimmune was founded in 2008 and is headquartered in Philadelphia, US
Report incorrect company information

Adaptimmune Office Locations

Adaptimmune has offices in Philadelphia and Milton
Philadelphia, US (HQ)
2010 Market St
Milton, GB
Park House Park Dr
Show all (2)
Report incorrect company information

Adaptimmune Financials and Metrics

Adaptimmune Financials

Adaptimmune's revenue was reported to be $8.98 m in FY, 2016
USD

Revenue (Q3, 2017)

27.2 m

EBIT (Q3, 2017)

(5 m)

Market capitalization (23-Apr-2018)

6.6 b

Cash (30-Sep-2017)

145.3 m
Adaptimmune's current market capitalization is $6.6 b.
Annual
USDFY, 2016

Revenue

9 m

General and administrative expense

9.9 m

R&D expense

25.5 m

Operating expense total

35.4 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

2.9 m328 k2.4 m2.9 m3.5 m27.2 m

General and administrative expense

5.9 m6.8 m5.4 m6.5 m7.7 m8.1 m

R&D expense

13.9 m16.2 m15.6 m18.6 m19.6 m24 m

Operating expense total

19.7 m(23 m)(21 m)(25.1 m)(27.3 m)(32.1 m)
Annual
USDFY, 2016

Cash

158.8 m

Accounts Receivable

149.5 k

Inventories

1.4 m

Current Assets

198.8 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

163.8 m150.9 m140.4 m170.6 m122 m145.3 m

Current Assets

238.6 m218.2 m199.5 m222.9 m237.7 m253.9 m

PP&E

13.8 m13.4 m15.1 m35.1 m38.9 m39.8 m

Total Assets

261.6 m239.6 m222.6 m266 m284.3 m301.4 m
Annual
USDFY, 2016

Net Income

(23 m)

Cash From Operating Activities

(48.2 m)

Cash From Investing Activities

17.8 m

Cash From Financing Activities

17 k
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(15.6 m)(22.1 m)(18.5 m)

Accounts Payable

2.4 m2.5 m3.2 m5.2 m
USDY, 2017

Revenue/Employee

91.2 k

Financial Leverage

1.3 x
Show all financial metrics

Adaptimmune Operating Metrics

Adaptimmune's Patent Applications was reported to be 69 in FY, 2016.
FY, 2016

Patent Applications

69

Patents Issued

173
Show all operating metrics
Report incorrect company information

Adaptimmune News and Updates

Report incorrect company information